Pathologische Diagnostik der Ovarialkarzinome

Für die Diagnostik des Ovarialkarzinoms ist noch immer die Histologie das wichtigste Werkzeug, idealerweise ergänzt durch ein geeignetes Panel von 4 – 6 immunhistochemischen Färbungen. Seit Zulassung der PARP-Inhibitoren gehört zudem der Nachweis von Mutationen in den Tumorsuppressorgenen BRCA1/2 im Tumorgewebe bei high-grade serösen Karzinomen zum Alltag.

• Literatur

• 1 Kurman RJ, Carcangiu ML, Herrington CS. et al. WHO Classification of Tumors of Female Reproductive Organs. Lyon: IARC; 2014
• 2 Kurman RJ, Shih IeM. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Americ J Pathol 2016; 186: 733-747
• 3 McCluggage WG, Judge MJ, Clarke BA. et al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 2015; 28: 1101-1122
• 4 Malpica A, Deavers MT, Tornos C. et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 2007; 31: 1168-1174
• 5 Hoang LN, Gilks BC. Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2. Advances in anatomic pathology 2017; PMID: 28914618
• 6 Vang R, Shih IeM, Kurman RJ. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 2013; 62: 44-58
• 7 Taylor J, McCluggage WG. Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm. Am J Surg Pathol 2015; 39: 983-992
• 8 Conlon N, Silva A, Guerra E. et al. Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type. Am J Surg Pathol 2016; 40: 395-403
• 9 Kobel M, Rahimi K, Rambau PF. et al. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. Int J Gynecol Pathol 2016; 35: 430-441
• 10 Capoluongo E, Ellison G, Lopez-Guerrero JA. et al. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Semin Oncol 2017; 44: 187-197
• 11 Cunningham JM, Cicek MS, Larson NB. et al. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Scientif Rep 2014; 4: 4026
• 12 Spreafico A, Oza AM, Clarke B. et al. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). Gynecol Oncol 2017; 144: 250-255